Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 14/20 | 0.44 |
| ▸ | MC3R | P41968 | 7/20 | 0.44 |
| ▸ | MC5R | P33032 | 7/20 | 0.44 |
| ▸ | MC1R | Q01726 | 6/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5729813 | 1.00 | MC4R (0.44) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL5730506 | 0.99 | MC4R (0.45) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL5730511 | 0.99 | MC4R (0.45) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL5730509 | 0.99 | MC4R (0.45) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL7027450 | 0.86 | HRH3 (0.54) | MC4RMC3RMC5RMC1RHRH3 | |
| Hydrochloric Acid SCHEMBL2584752 | 0.86 | MC4R (0.43) | MC4RMC3RMC5RMC1RKCNH2 | |
| Hydrochloric Acid SCHEMBL14658470 | 0.86 | MC4R (0.43) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL2304570 | 0.85 | MEN1 (0.46) | MC4RMC3RMC5RALDH1A1 | |
| SCHEMBL2304994 | 0.85 | MEN1 (0.46) | MC4RMC3RMC5RALDH1A1 | |
| SCHEMBL21029282 | 0.85 | RORC (0.42) | MC4RALDH1A1HRH3PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563074-B | Piperazine derivatives | 安斯泰来制药株式会社 | 2021-09-28 | — | — | CN | disclosed |
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2019-07-04 | — | — | US | disclosed |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| US-10301286-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2019-05-28 | — | — | US | disclosed |
| CN-109563074-A | Bridged piperazine derivatives | 安斯泰来制药株式会社 | 2019-04-02 | — | — | CN | disclosed |
| WO-2017022733-A1 | PIPERAZINE DERIVATIVE | アステラス製薬株式会社 | 2017-02-09 | — | — | WO | disclosed |
| EP-1372653-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7015235-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20060035935-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | GOULET MARK T | 2006-02-16 | — | — | US | disclosed |
| US-20040097546-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710988-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | MC4R 2/4885MC3R 14/4885MC5R 6/4885 |
| US-20060035935-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
| US-20040097546-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | MC4R 1/4885MC3R 3/4885MC5R 2/4885 |
| US-10301286-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | MC4R 2/4885MC3R 19/4885MC5R 6/4885 |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | GPR4, MC4R, TRPC4 | MC4R 2/4885MC3R 14/4885MC5R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.